TMCI vs. SGHT, ORGO, ANGO, BVS, SIBN, MDXG, ATRC, SINT, AORT, and CATX
Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Sight Sciences (SGHT), Organogenesis (ORGO), AngioDynamics (ANGO), Bioventus (BVS), SI-BONE (SIBN), MiMedx Group (MDXG), AtriCure (ATRC), Sintx Technologies (SINT), Artivion (AORT), and Perspective Therapeutics (CATX). These companies are all part of the "medical" sector.
Treace Medical Concepts (NASDAQ:TMCI) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Treace Medical Concepts currently has a consensus price target of $12.21, indicating a potential upside of 107.73%. Sight Sciences has a consensus price target of $4.70, indicating a potential downside of 28.35%. Given Treace Medical Concepts' higher possible upside, analysts plainly believe Treace Medical Concepts is more favorable than Sight Sciences.
Treace Medical Concepts has higher revenue and earnings than Sight Sciences. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 24.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 28.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Treace Medical Concepts has a net margin of -27.93% compared to Sight Sciences' net margin of -67.18%. Treace Medical Concepts' return on equity of -39.66% beat Sight Sciences' return on equity.
Treace Medical Concepts has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500.
Treace Medical Concepts received 9 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 53.33% of users gave Treace Medical Concepts an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
In the previous week, Treace Medical Concepts had 1 more articles in the media than Sight Sciences. MarketBeat recorded 9 mentions for Treace Medical Concepts and 8 mentions for Sight Sciences. Treace Medical Concepts' average media sentiment score of 0.84 beat Sight Sciences' score of 0.64 indicating that Treace Medical Concepts is being referred to more favorably in the media.
Summary
Treace Medical Concepts beats Sight Sciences on 12 of the 17 factors compared between the two stocks.
Get Treace Medical Concepts News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Treace Medical Concepts Competitors List
Related Companies and Tools
